Monthly information on share capital and company voting rights

Rhea-AI Summary

Cellectis (Euronext Growth: CLLS) reports monthly share capital and voting rights as of January 31, 2026. The company lists 100,590,994 total shares and 105,825,481 total voting rights. ISIN: FR0010425595. Contact details provided for media and investors.

News Market Reaction – CLLS

-1.13%

2 alerts

-1.13% News Effect

-$3M Valuation Impact

$271.94M Market Cap

0.3x Rel. Volume

On the day this news was published, CLLS declined 1.13%, reflecting a mild negative market reaction. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $3M from the company's valuation, bringing the market cap to $271.94M at that time.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement provides an updated snapshot of Cellectis’s capital structure, stating 100,590,994...

Analysis

This announcement provides an updated snapshot of Cellectis’s capital structure, stating 100,590,994 shares and 105,825,481 voting rights as of Jan 31, 2026. Similar monthly disclosures on Dec 3 and Jan 5 helped keep investors informed on potential dilution and control. Alongside an effective Form F-3 shelf and recent clinical and strategic updates, investors may track how future capital decisions interact with pipeline progress and market conditions.

Key Figures

Total shares: 100,590,994 Total voting rights: 105,825,481 Reference date: 01/31/2026

3 metrics

Total shares 100,590,994 Total number of shares in the capital as of 01/31/2026

Total voting rights 105,825,481 Total number of voting rights as of 01/31/2026

Reference date 01/31/2026 Date of share capital and voting rights information

Historical Context

5 past events · Latest: Jan 08 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jan 08	Strategy and pipeline update	Positive	-1.6%	Outlined 2026 allogeneic CAR-T strategy and multiple clinical catalysts.
Jan 05	Monthly share/votes report	Neutral	-5.4%	Published December 31, 2025 share count and total voting rights.
Dec 15	Arbitral decision	Neutral	+2.4%	Reported partial termination of a Servier license for UCART19 V1.
Dec 08	Clinical data update	Positive	-2.5%	Presented Phase 1 NATHALI-01 eti-cel data with high ORR and CR rates.
Dec 03	Monthly share/votes report	Neutral	+3.6%	Disclosed November 30, 2025 share count and voting rights.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Clinical and strategy updates tended to see negative or muted next-day moves, while routine share-capital disclosures have produced mixed but generally modest reactions.

Recent Company History

Over the last few months, Cellectis combined regular corporate updates with significant clinical and strategic news. A Dec 3, 2025 and Jan 5, 2026 pattern of monthly share-capital and voting-rights disclosures paralleled the current announcement. In contrast, the ASH 2025 eti-cel data and the Jan 8, 2026 2026 strategy and catalysts update highlighted strong response rates and longer-term milestones, yet both saw negative price reactions within 24 hours, suggesting a history of cautious market responses to positive fundamentals.

Key Terms

isin

1 terms

isin financial

"Listing market: Euronext Growth ISIN code: FR0010425595"

A 12-character International Securities Identification Number (ISIN) is a unique code that acts like a passport for a specific stock, bond or other tradable security so it can be identified worldwide. Investors and systems use it to ensure they are buying, selling and tracking the exact same instrument across exchanges and data feeds, which prevents costly mix-ups and makes portfolio reporting, settlement and regulatory checks simpler and more reliable.

View in glossary

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

(Article 223-16 of General Regulation of the French financial markets authority)

PARIS, Feb. 04, 2026 (GLOBE NEWSWIRE) --

Listing market: Euronext Growth

ISIN code: FR0010425595

Date	Total number of shares in the capital	Total number of voting rights
01/31/2026	100,590,994	105,825,481

For further information on Cellectis, please contact:

Media contacts:

Pascalyne Wilson, Director, Communications, +33 (0)7 76 99 14 33, media@cellectis.com
Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93

Investor Relations contact:

Arthur Stril, Chief Financial Officer & Chief Business Officer, investors@cellectis.com 

Attachment

• Voting_Rights_PR_January_2026_EN

FAQ

How many shares did Cellectis (CLLS) have outstanding on January 31, 2026?

Cellectis reported 100,590,994 total shares outstanding as of January 31, 2026. According to Cellectis, this figure represents the company's registered share capital on that date for Euronext Growth reporting purposes.

What were Cellectis (CLLS) total voting rights on January 31, 2026?

Cellectis recorded 105,825,481 total voting rights on January 31, 2026. According to Cellectis, the voting rights total reflects shares carrying voting power, including double-vote or treasury share adjustments where applicable.

Where is Cellectis (CLLS) listed and what is its ISIN code?

Cellectis is listed on Euronext Growth and its ISIN code is FR0010425595. According to Cellectis, this listing and ISIN identify the company's securities for trading and regulatory disclosures in France.

Who should investors contact for more information about Cellectis (CLLS) shareholder data?

Investors can contact Arthur Stril, Chief Financial Officer & Chief Business Officer, via investors@cellectis.com. According to Cellectis, the investor relations contact handles questions on share capital and voting rights disclosures.

Does the January 2026 voting rights report for Cellectis (CLLS) include a detailed attachment?

Yes, the disclosure references an attachment named Voting_Rights_PR_January_2026_EN. According to Cellectis, the attachment contains the formal breakdown used for the monthly regulatory filing and investor review.